ID   TLBR-1
AC   CVCL_L177
SY   TLBR 1; TLBR1; T-cell Lymphoma BReast-1
DR   ATCC; CRL-3027
DR   Cosmic; 2814460
DR   DSMZ; ACC-904
DR   DSMZCellDive; ACC-904
DR   GEO; GSM2527949
DR   Wikidata; Q54972607
RX   PubMed=21425149;
RX   PubMed=22791880;
RX   PubMed=28356514;
CC   Doubling time: 55 hours (PubMed=21425149); ~30-40 hours (DSMZ=ACC-904).
CC   Sequence variation: Mutation; HGNC; HGNC:11364; STAT3; Simple; p.Ser614Arg (c.1842C>G); Zygosity=Unspecified (PubMed=28356514).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Discontinued: ATCC; CRL-3027; true.
CC   Derived from site: In situ; Breast; UBERON=UBERON_0000310.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC=CRL-3027; DSMZ=ACC-904
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11,14
ST   D16S539: 12
ST   D18S51: 13,14
ST   D19S433: 13,14
ST   D21S11: 28,29,30
ST   D2S1338: 17,26
ST   D3S1358: 17,18
ST   D5S818: 11,13 (ATCC=CRL-3027)
ST   D5S818: 11,13,14 (DSMZ=ACC-904)
ST   D7S820: 8,10
ST   D8S1179: 12,13
ST   FGA: 22,24
ST   Penta D: 10,11
ST   Penta E: 14,19
ST   TH01: 7,9
ST   TPOX: 8
ST   vWA: 16,17
DI   NCIt; C37194; Anaplastic large cell lymphoma, ALK-negative
DI   ORDO; Orphanet_300903; ALK-negative anaplastic large cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   42Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 16
//
RX   PubMed=21425149; DOI=10.1002/cncr.25654; PMCID=PMC4175713;
RA   Lechner M.G., Lade S., Liebertz D.J., Prince H.M., Brody G.S.,
RA   Webster H.R., Epstein A.L.;
RT   "Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell
RT   lymphoma: establishment and characterization of a model cell line
RT   (TLBR-1) for this newly emerging clinical entity.";
RL   Cancer 117:1478-1489(2011).
//
RX   PubMed=22791880; DOI=10.1158/1078-0432.CCR-12-0101;
RA   Lechner M.G., Megiel C., Church C.H., Angell T.E., Russell S.M.,
RA   Sevell R.B., Jang J.K., Brody G.S., Epstein A.L.;
RT   "Survival signals and targets for therapy in breast implant-associated
RT   ALK -- anaplastic large cell lymphoma.";
RL   Clin. Cancer Res. 18:4549-4559(2012).
//
RX   PubMed=28356514; DOI=10.1073/pnas.1700682114; PMCID=PMC5393253;
RA   Chen J., Zhang Y., Petrus M.N., Xiao W.-M., Nicolae A., Raffeld M.,
RA   Pittaluga S., Bamford R.N., Nakagawa M., Ouyang S.T.-Y., Epstein A.L.,
RA   Kadin M.E., Del Mistro A., Woessner R.D., Jaffe E.S., Waldmann T.A.;
RT   "Cytokine receptor signaling is required for the survival of ALK-
RT   anaplastic large cell lymphoma, even in the presence of JAK1/STAT3
RT   mutations.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3975-3980(2017).
//